Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs

Suzuki, Yuta; Ishiguro, Hiroshi

doi:10.1016/j.dmpk.2021.100424

Cited by 163 publications

(111 citation statements)

References 63 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…These articles describe 66 cases of mRNA-VAM. BNT162b2 (manufacturer: Pfizer® [New York City, NY, USA]-BioNTech® [Mainz, Germany], also known as Tozinameran or Comirnaty [ 16 ]) was administered in 53 cases (80.3%) and mRNA-1273 (manufacturer: Moderna® [Cambridge, MA, USA], also known as Elasomeran or Spikevax [ 16 ]) in 13 cases (19.7%).…”

Section: Resultsmentioning

confidence: 99%

Diagnostik von messenger Ribonukleinsäure (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) impfassoziierten Myokarditiden – ein systematischer Review

Federspiel

Ramsthaler²,

Kettner³

et al. 2022

Rechtsmedizin

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Diagnostik von messenger Ribonukleinsäure (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) impfassoziierten Myokarditiden – ein systematischer Review

Federspiel

Ramsthaler²,

Kettner³

et al. 2022

Rechtsmedizin

View full text Add to dashboard Cite

“…Inflammatory cytokines, such as IL-6, IL-1β, etc., are released due to the LNP component of the mRNA vaccines [9]. LNPs are also components of the small interfering RNA therapeutics (Patisiran) [111]. Patisiran increases IL-6 and interferon-inducible protein 10 (IP10) levels after infusion [112].…”

Section: Inflammatory Cytokinesmentioning

confidence: 99%

What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions

et al. 2022

View full text Add to dashboard Cite

COVID-19 vaccines have been used to counteract the global COVID-19 pandemic. While these are effective, adverse reactions have been reported, such as injection-site pain, muscle ache, fever, palpitation, and chest discomfort. The release of inflammatory cytokines, such as interleukin (IL)-6 and IL-1β, is a potential mechanism for post-vaccine side-effects. Chest discomfort after the vaccination, including myocarditis and acute coronary syndrome, is a particularly serious adverse reaction. It is important to be familiar with the differential diagnoses of chest discomfort and organ-specific diseases associated with COVID-19 vaccines as the preparation for booster shots and vaccinations among children aged 5–11 years begins. High-intensity exercise, alcohol, tobacco smoking, and baths promote inflammatory cytokines, such as IL-6, which may exacerbate the adverse reactions after vaccination. Japanese data show that deaths during baths are the most common for several days after mRNA vaccination. Additionally, alcohol and tobacco smoking were identified as predictive factors of lower antibody titers after vaccination. In this review, we aimed to provide a few recommendations to prevent vaccine-associated disease.

show abstract

“…In 2018, the FDA and the EMA approved a therapeutic drug for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) based on siRNA LNPs, ONPATTRO™ (patisiran) [ 55 , 56 ]. In patisiran, the weight ratio of total lipids and siRNAs is 12.1, and the composition of these LNPs, which could effectively target the transthyretin of hepatocytes, includes ionizable lipid, phospholipid, cholesterol, and PEG lipid [ 125 ]. To date, LNPs are the most frequently studied in vivo delivery carriers, and they can silence target genes by encapsulating and delivering specific siRNAs.…”

Section: Np Delivery—a Platform Ensuring the Efficacy And Stability O...mentioning

confidence: 99%

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Zhang

Almazi

Ong

et al. 2022

IJMS

View full text Add to dashboard Cite

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At present, the Food and Drug Administration (FDA) has issued emergency approval for the use of some antiviral drugs. However, these drugs still have limitations in the specific treatment of COVID-19, and as such, new treatment strategies urgently need to be developed. RNA-interference-based gene therapy provides a tractable target for antiviral treatment. Ensuring cell-specific targeted delivery is important to the success of gene therapy. The use of nanoparticles (NPs) as carriers for the delivery of small interfering RNA (siRNAs) to specific tissues or organs of the human body could play a crucial role in the specific therapy of severe respiratory infections, such as COVID-19. In this review, we describe a variety of novel nanocarriers, such as lipid NPs, star polymer NPs, and glycogen NPs, and summarize the pre-clinical/clinical progress of these nanoparticle platforms in siRNA delivery. We also discuss the application of various NP-capsulated siRNA as therapeutics for SARS-CoV-2 infection, the challenges with targeting these therapeutics to local delivery in the lung, and various inhalation devices used for therapeutic administration. We also discuss currently available animal models that are used for preclinical assessment of RNA-interference-based gene therapy. Advances in this field have the potential for antiviral treatments of COVID-19 disease and could be adapted to treat a range of respiratory diseases.

show abstract

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs

Cited by 163 publications

References 63 publications

Diagnostik von messenger Ribonukleinsäure (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) impfassoziierten Myokarditiden – ein systematischer Review

Diagnostik von messenger Ribonukleinsäure (mRNA) severe acute respiratory syndrome-corona virus‑2 (SARS-CoV‑2) impfassoziierten Myokarditiden – ein systematischer Review

What Should We Do after the COVID-19 Vaccination? Vaccine-Associated Diseases and Precautionary Measures against Adverse Reactions

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Contact Info

Product

Resources

About